They have observed that the usage of MLH1 and PMS2 for differentiation between healthy patients and cancer patients was successful; the use of KRAS was for better and more conclusive differentiation between gastric cancer and colorectal cancer patients [59,98,99]. This evidence concerns the gene PMS2 and gastric cancer.